PBLD

Across TCGA pan-cancer cohorts, PBLD mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PBLD data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PBLD mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PBLD expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where PBLD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.669	0.409	<.001	112	view →
CCRCC	OS	Quartile	III,IV	0.884	0.388	.001	60	view →
HNSC	DFS	Tertile	III,IV	0.964	0.284	.006	31	view →
LSCC	DFS	Median	II,III,IV	0.546	0.851	.011	18	view →
LUAD	DFS	Quartile	II,III,IV	0.634	0.993	.006	8	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PBLD–PDAC (OS)

Open the PDAC breakdown →